SmithKline/Incyte joint venture diaDexus will commercialize diagnostics based on SB discovery research.
SB/INCYTE DIADEXUS JOINT VENTURE WILL COMMERCIALIZE DIAGNOSTIC applications of SmithKline Beecham's drug discovery research, SmithKline announced Sept. 3. The 50/50 joint venture, diaDexus, "has exclusive rights to develop diagnostic tests based on novel molecular targets and genetic alterations identified as part of SB's drug discovery efforts and from SB's collaboration with Human Genome Sciences," SmithKline said. Incyte and SmithKline are contributing $25 mil. in funding for the new company, as well as "various additional technologies and intellectual property rights in the diagnostic field," the companies said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth